In November 2021, Congress introduced a working draft of the Build Back Better Act. This legislation includes proposals that could drive some of the most material changes in drug pricing in the history of the Medicare Parts B and D programs. The changes are sweeping, with potential for some to be implemented as soon as 2023. This article, which appeared in PM360, a pharmaceutical marketing journal, focuses on three considerations for reducing prescription drug prices in the United States:
- Government negotiation of Medicare drug prices
- Inflation penalties for drug pricing
- Biosimilar drug reimbursement